ES2150916T3 - Utilizacion del acido gentisico o del alcohol gentisilico para estabilizar peptidos y proteinas radiomarcados. - Google Patents

Utilizacion del acido gentisico o del alcohol gentisilico para estabilizar peptidos y proteinas radiomarcados.

Info

Publication number
ES2150916T3
ES2150916T3 ES92917956T ES92917956T ES2150916T3 ES 2150916 T3 ES2150916 T3 ES 2150916T3 ES 92917956 T ES92917956 T ES 92917956T ES 92917956 T ES92917956 T ES 92917956T ES 2150916 T3 ES2150916 T3 ES 2150916T3
Authority
ES
Spain
Prior art keywords
gentisilic
proteins
alcohol
acid
stabilize
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92917956T
Other languages
English (en)
Inventor
Edward A Deutsch
Wilhelmus Theodorus Goedemans
Jong Martinus Theodorus De
Kathleen M Miller
James W Brodack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Inc
Original Assignee
Mallinckrodt Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Medical Inc filed Critical Mallinckrodt Medical Inc
Application granted granted Critical
Publication of ES2150916T3 publication Critical patent/ES2150916T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

EL ACIDO GENTISICO Y SUS DERIVADOS INHIBEN SUSTANCIALMENTE LA AUTORRADIOLISIS DE PEPTIDOS. EL ACIDO GENTISICO O SUS DERIVADOS SE PUEDEN UTILIZAR TAMBIEN JUNTO CON OTROS ESTABILIZADORES TALES COMO INOSITOL, ACIDO ASCORBICO O CITRATO PARA INHIBIR LA AUTORRADIOLISIS DE PEPTIDOS RADIOETIQUETADOS.
ES92917956T 1991-08-29 1992-07-31 Utilizacion del acido gentisico o del alcohol gentisilico para estabilizar peptidos y proteinas radiomarcados. Expired - Lifetime ES2150916T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75182591A 1991-08-29 1991-08-29

Publications (1)

Publication Number Publication Date
ES2150916T3 true ES2150916T3 (es) 2000-12-16

Family

ID=25023648

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92917956T Expired - Lifetime ES2150916T3 (es) 1991-08-29 1992-07-31 Utilizacion del acido gentisico o del alcohol gentisilico para estabilizar peptidos y proteinas radiomarcados.

Country Status (11)

Country Link
US (1) US5384113A (es)
EP (1) EP0600992B1 (es)
JP (1) JP3853354B2 (es)
AT (1) ATE196428T1 (es)
AU (1) AU2462592A (es)
CA (1) CA2113995C (es)
DE (1) DE69231469T2 (es)
DK (1) DK0600992T3 (es)
ES (1) ES2150916T3 (es)
GR (1) GR3035067T3 (es)
WO (1) WO1993004702A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897255A (en) * 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5985240A (en) * 1989-08-09 1999-11-16 Rhomed Incorporated Peptide radiopharmaceutical applications
GB9004017D0 (en) * 1990-02-22 1990-04-18 Krenning Eric P Improvements in or relating to organic compounds
EP0626170A3 (en) * 1993-05-10 1996-03-27 Sandoz Ltd Stabilization of pharmacoligically active compounds in controlled release compositions.
US5830431A (en) * 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
CA2279349C (en) * 1996-02-02 2007-09-25 Rhomed Incorporated Ascorbate-stabilized radiopharmaceutical method and composition
US6066309A (en) * 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US20010055563A1 (en) 1999-09-09 2001-12-27 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
WO1997033580A1 (en) * 1996-03-11 1997-09-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Maintaining kidney function during surgery or trauma
US5859043A (en) * 1996-06-11 1999-01-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for maintaining kidney function during surgery or severe trauma under general anesthesia
AUPO066096A0 (en) * 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
US6027710A (en) * 1996-09-18 2000-02-22 Nihon Medi-Physiscs Co., Ltd. Radiation-protecting agent
US6468971B1 (en) 1997-03-05 2002-10-22 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Maintaining kidney function during surgery or trauma
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
WO2000018440A1 (en) * 1998-09-25 2000-04-06 Mallinckrodt Inc. Somatostatin receptor radioligand with increased uptake
WO2001000637A1 (en) * 1999-06-29 2001-01-04 Mallinckrodt Inc. Group (vii) transition-metal complexes with multidentate aminopolycarboxylate ligands and a kit for producing them
US20020122768A1 (en) * 2000-07-06 2002-09-05 Shuang Liu Stable radiopharmaceutical compositions and methods for preparation thereof
US6989138B2 (en) 2000-10-24 2006-01-24 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic thioethers and hydrophilic 6-hydroxy chromans
US6881396B2 (en) * 2000-10-24 2005-04-19 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic 6-hydroxy-chromans
US6902718B2 (en) * 2000-10-24 2005-06-07 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic thioethers
JP2004529884A (ja) * 2001-02-26 2004-09-30 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー 金属放射性医薬のためのアスコルビン酸類似体
US6567492B2 (en) 2001-06-11 2003-05-20 Eastern Isotopes, Inc. Process and apparatus for production of F-18 fluoride
US7238338B1 (en) 2001-06-22 2007-07-03 Triumf System and method for the large scale labeling of compounds with radiohalogens
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
US7018614B2 (en) 2002-11-05 2006-03-28 Eastern Isotopes, Inc. Stabilization of radiopharmaceuticals labeled with 18-F
AU2002337926B8 (en) 2002-11-05 2008-02-28 Ion Beam Applications S.A. Stabilization of radiopharmaceuticals labeled with 18-F
SG144160A1 (en) * 2003-07-24 2008-07-29 Bracco Imaging Spa Stable radiopharmaceutical compositions and methods for their preparation
US7485283B2 (en) * 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
JP5112062B2 (ja) * 2005-06-14 2013-01-09 日本メジフィジックス株式会社 放射性画像診断剤
GB0514087D0 (en) * 2005-07-11 2005-08-17 Ge Healthcare Ltd Stabilised radiopharmaceutical compositions
US20100254902A1 (en) * 2007-11-07 2010-10-07 Jan Van Den Bos Stabilization of radiopharmaceuticals
WO2009086062A1 (en) * 2007-12-21 2009-07-09 Lyotropic Therapeutics, Inc. Stabilized formulations of peptides and proteins
ES2767973T3 (es) 2008-02-29 2020-06-19 Lantheus Medical Imaging Inc Agentes de contraste para aplicaciones que comprenden formación de imágenes de perfusión
CN107261159B (zh) 2009-04-15 2021-01-12 兰休斯医疗成像公司 使用抗坏血酸稳定化放射性药物组合物
TWI589302B (zh) 2010-02-08 2017-07-01 藍瑟斯醫學影像公司 用於合成造影劑及其中間體之方法及裝置
WO2011147762A2 (en) 2010-05-25 2011-12-01 Bayer Pharma Aktiengesellschaft Stabilized radiopharmaceutical composition
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
GB201504064D0 (en) * 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes
BR112019009172A2 (pt) * 2016-11-04 2019-07-16 Clarity Pharmaceuticals Pty Ltd formulações para radioterapia e diagnóstico por imagem.
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
CN114835690B (zh) * 2022-07-04 2022-09-27 北京先通国际医药科技股份有限公司 含化合物i的液体组合物的制备方法、及在心肌灌注pet显像中的用途
CN115015441B (zh) * 2022-07-14 2023-08-18 原子高科股份有限公司 一种测定镥[177Lu]氧奥曲肽注射液中稳定剂含量的方法
WO2024036372A1 (en) * 2022-08-16 2024-02-22 Clarity Pharmaceuticals Limited Formulations for radiotherapy and diagnostic imaging and use thereof in treatment, diagnosis and imaging diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497744A (en) * 1978-03-31 1985-02-05 Mallinckrodt, Inc. Gentisic acid salts as radiographic scanning agent stabilizers
US4232000A (en) * 1978-06-28 1980-11-04 The Procter & Gamble Company Radioactive scanning agents with stabilizer
US4229427A (en) * 1978-06-28 1980-10-21 The Procter & Gamble Company Radioactive scanning agents with hydroquinone stabilizer
US4232284A (en) * 1979-05-07 1980-11-04 Power Parts, Inc. Ignition coil and electrical connector therefor
US4504463A (en) * 1982-06-10 1985-03-12 Mallinckrodt, Inc. Process for making a lyophilized product for use in skeletal imaging
US4504462A (en) * 1982-06-10 1985-03-12 Mallinckrodt, Inc. Process for making a lyophilized product for use in skeletal imaging
US4440738A (en) * 1982-06-10 1984-04-03 Mallinckrodt, Inc. Stable radiographic imaging agents
US4707353A (en) * 1982-12-08 1987-11-17 Mallinckrodt, Inc. Radiographic imaging agents
US4510125A (en) * 1982-12-08 1985-04-09 Mallinckrodt, Inc. Process for making lyophilized radiographic imaging kit
JPS59199636A (ja) * 1983-04-26 1984-11-12 Nippon Mejifuijitsukusu Kk 放射性診断剤
US4942231A (en) * 1984-05-24 1990-07-17 Mallinckrodt, Inc. Method of preparing a chlorinated, brominated, radio-brominated, iodinated and/or radioiodinated aromatic or heteroaromatic compound
EP0313712B1 (de) * 1987-10-30 1992-07-29 SORIN BIOMEDICA S.p.A. Stabile radiodiagnostische Präparate und ihre Herstellung
GB2239178B (en) * 1987-07-10 1991-11-27 Sandoz Ltd Somatostatin analogues for the treatment of breast cancer
MY106120A (en) * 1988-12-05 1995-03-31 Novartis Ag Peptide derivatives.
US5219556A (en) * 1990-07-09 1993-06-15 Mallinckrodt Medical, Inc. Stabilized therapeutic radiopharmaceutical complexes
US5093105A (en) * 1991-04-09 1992-03-03 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats

Also Published As

Publication number Publication date
EP0600992A1 (en) 1994-06-15
GR3035067T3 (en) 2001-03-30
JPH06510539A (ja) 1994-11-24
CA2113995A1 (en) 1993-03-18
AU2462592A (en) 1993-04-05
EP0600992B1 (en) 2000-09-20
DK0600992T3 (da) 2000-10-09
US5384113A (en) 1995-01-24
ATE196428T1 (de) 2000-10-15
JP3853354B2 (ja) 2006-12-06
CA2113995C (en) 2003-04-22
DE69231469D1 (de) 2000-10-26
DE69231469T2 (de) 2001-01-25
WO1993004702A1 (en) 1993-03-18

Similar Documents

Publication Publication Date Title
ES2150916T3 (es) Utilizacion del acido gentisico o del alcohol gentisilico para estabilizar peptidos y proteinas radiomarcados.
IT1203515B (it) Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
DE69309487T2 (de) Peripheralisierung hämatopoietischer stammzellen
ES2054842T3 (es) Analogo del factor viii, procedimiento de preparacion y composicion farmaceutica que lo contiene.
DE3875425D1 (de) Vasokinetisch wirkende polyungesaettigte saeuren und sie enthaltende pharmazeutische oder kosmetische zubereitungen.
LV10907A (lv) Interferona polietilenglikola atvasinajums
PT883687E (pt) Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes
HUP0003592A2 (hu) LH-RH peptid analógok, alkalmazásuk, és ezeket tartalmazó gyógyászati készítmények
DK0668769T3 (da) Egebarkekstrakt-relaterede syntetiske sammensætninger og fremgangsmåde til deres anvendelse
DK204791D0 (da) Hidtil ukendt farmaceutisk praeparat
DE3686794D1 (de) Reinigung des natuerlichen kolonie-stimulierenden faktors-1.
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
ES2134189T3 (es) Procedimiento para la preparacion de un producto de celulosa oxidado neutralizado y uso del mismo.
ATE172108T1 (de) Verwendung von diglycerinestern gegen unreine haut
HUP9900506A2 (hu) Protrombinszármazékok
DK0666739T3 (da) Intravenøs opløsning som formindsker protein- og vandtab fra kroppen
GR880100775A (el) Παράγοντας ενεργοποιήσεως ουδετεροφίλων.
ITRM910554A1 (it) Composizioni farmaceutiche stabilizzate
FR1923M (fr) Concentré d'amino-acides et compositions contenant ce concentré.
HUP9602024A2 (hu) Aminosavtartalmú, külsőlegesen használható, gyógyhatású készítmény
DE3863200D1 (de) In der krebstherapie verwendbare zusammensetzung auf der basis von aminosaeure und vitaminen.
ATE81134T1 (de) Peptide.
SE8200757L (sv) Biologiskt aktiva peptider
DE69518319D1 (de) Verwendung von oberflächenaktiven substanzen zur stabilisierung von peptiden und proteinen zur radiopharmazeutischen verwendung
MX9207199A (es) Composicion farmaceutica estabilizada de il2 recombinante humana no glicosilada en forma reducida, que comprende acido citrico, manitol y procedimien to para su preparacion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 600992

Country of ref document: ES